Generic Name and Formulations:
Triazolam 0.125mg, 0.25mg+; tabs; +scored.
Company:
Pfizer Inc.
Short-term (7–10 days) treatment of insomnia.
≥18yrs: 0.125–0.25mg at bedtime; max 0.5mg. Elderly or debilitated: initially 0.125mg, max 0.25mg. Max 1 month/℞.
<18yrs: not recommended.
Benzodiazepine.
Concomitant ketoconazole, itraconazole, nefazodone, other potent CYP3A inhibitors. Pregnancy (Cat.X).
Overdosage may occur at 2mg. Suicidal tendencies. Depression. Pulmonary, renal, or hepatic disease. Sleep apnea. Drug or alcohol abuse. Reevaluate if used ≥2–3 weeks. Avoid abrupt cessation. Discontinue if excitement or daytime anxiety occurs. Nursing mothers: not recommended.
See Contraindications; other azole antifungals: not recommended. Potentiates CNS depression with alcohol, other CNS depressants. Potentiated by ranitidine, grapefruit juice, isoniazid, oral contraceptives. Reduce triazolam dose with cimetidine, erythromycin, other macrolides. Caution with fluvoxamine, diltiazem, verapamil, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A.
CNS depression, complex sleep-related behaviors (eg, sleep-driving), ataxia, headache, nausea, paradoxical excitement, anxiety, worsening of insomnia, abnormal behavior, amnesia; anaphylaxis, angioedema.
Tabs—10, 500